je.st
news
Tag: evaluating
New Data from Phase 2 Study Evaluating KEYTRUDA (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
2016-06-05 19:43:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated findings from a study evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with advanced cancers characterized as deficient for DNA mismatch repair (MMR). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
New Data Evaluating KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
2016-06-04 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreated patients with NSCLC; the study showed overall response rates (ORR) ranging from 48 to 71 percent, depending on the therapy used. Language: English Contact: MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA
2016-06-01 06:09:24| drugdiscoveryonline Home Page
Cerulean Pharma Inc., a clinical-stage company developing nanoparticle-drug conjugates (NDCs), recently announced that the first patient has been dosed in an open-label, single center Phase 1/2 clinical trial of its lead NDC candidate, CRLX101, in combination with LYNPARZA (olaparib) in patients with advanced solid tumors
Tags: with
trial
combination
phase
Hawk moths have a second nose for evaluating flowers
2016-05-27 12:00:00| LifeSciencesWorld
[NEWS] IMAGE:Â A Manduca sexta moth visits the flowers of Nicotiana attenuata, a wild tobacco species. The nocturnal moths are attracted by floral volatiles, but also visit flowers without scent. Credit: Danny Kessler / Max …
Tags: flowers
evaluating
nose
hawk
Pasternack's 60 GHz Development System Offers A Fast, Out-Of-The-Box Experience For Evaluating High Bandwidth Data Rates In The Unlicensed 60 GHz ISM Frequency Spectrum
2016-05-20 08:42:43| rfglobalnet Home Page
Pasternack, a leading provider of RF, microwave and millimeter wave products, introduces the newPEM009-KIT 60 GHz development systemwhich offers designers the ability to perform product development and experimentation of single and multi-carrier high bandwidth modulation covering 57 to 64 GHz in the globally unlicensed ISM frequency spectrum.
Tags: high
system
data
development
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] next »